Although the therapeutic efficacy of HDAC and PI3K inhibitors in ccRCC has been validated in the in vitro and in vivo experiments, further clinical trials are required to comprehensively estimate their therapeutic benefits. This evidence concerns the gene HDAC9 and nonpapillary renal cell carcinoma.